---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-027314"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2026-08-12T20:10:36+00:00"
generated_at: "2026-08-12T20:12:38.035029+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical Q2 2026 revenue up 82% to $0.6M; net loss $3.7M; AKI trial 223/339

## Summary
- Q2 net revenue $0.6M, up 82% vs $0.3M; gross margin 91% (vs 92%).
- Net loss $3.7M ($0.91/share) vs $2.0M ($1.77/share) on higher R&D ($2.5M) and G&A ($1.8M).
- Cash $7.0M at June 30, 2026, down from $12.0M at Dec 31, 2025.
- NEUTRALIZE-AKI trial enrolled 223 of 339 adult AKI patients; completion expected year-end/Q1 2027.
- CMS granted ICD-10-PCS codes for SCD therapy, effective Oct 1, 2026; added 3 children's hospitals (20 total).

## SEC filing metadata
- accession: 0001437749-26-027314
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2026-08-12T20:10:36+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000143774926027314/0001437749-26-027314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000143774926027314/icu20260607_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-027314
- JSON: https://secwatch.observer/filing/0001437749-26-027314.json
- Plain text: https://secwatch.observer/filing/0001437749-26-027314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.